Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, Vamvakas L, Kotsakis A, Potamianou A, Georgoulias V. Ignatiadis M, et al. Among authors: vamvakas l. Oncology. 2006;71(3-4):159-63. doi: 10.1159/000106064. Epub 2007 Jul 17. Oncology. 2006. PMID: 17646699 Clinical Trial.
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulias V, Mavroudis D. Bozionelou V, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2009 Sep;64(4):785-91. doi: 10.1007/s00280-009-0928-6. Epub 2009 Jan 22. Cancer Chemother Pharmacol. 2009. PMID: 19159931 Clinical Trial.
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. Polyzos A, et al. Among authors: vamvakas l. Breast Cancer Res Treat. 2010 Jan;119(1):95-104. doi: 10.1007/s10549-009-0468-0. Epub 2009 Jul 28. Breast Cancer Res Treat. 2010. PMID: 19636702 Clinical Trial.
Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group. Ardavanis A, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2006 Dec;58(6):742-8. doi: 10.1007/s00280-006-0236-3. Epub 2006 May 23. Cancer Chemother Pharmacol. 2006. PMID: 16718470 Clinical Trial.
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D. Kalbakis K, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2008 Aug;62(3):449-56. doi: 10.1007/s00280-007-0624-3. Epub 2007 Oct 25. Cancer Chemother Pharmacol. 2008. PMID: 17960381
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V. Katopodis O, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2011 Feb;67(2):361-8. doi: 10.1007/s00280-010-1329-6. Epub 2010 Apr 29. Cancer Chemother Pharmacol. 2011. PMID: 20428874 Clinical Trial.
83 results